2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2803

Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Abstract Number: 1208

Canakinumab In Patients With FMF
Abstract Number: 270

Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a 12-Week Pooled Post-Hoc Analysis For Efficacy
Abstract Number: 1783

Canakinumab Treatment In Active Hyper-IgD With Periodic Fever Syndrome
Abstract Number: 2747

Canakinumab Treatment In Schnitzler’s Syndrome: A Multi-Center Randomized Placebo-Controlled 4-Month Study
Abstract Number: 1206

Canakinumab Treatment Regimens In CAPS Patients
Abstract Number: 590

Candidate Urinary Biomarkers May Predict The Future Development Of Renal Functional Loss With Lupus Nephritis In Children and Adults
Abstract Number: 853

Capillaroscopy Compared With Color Doppler Ultrasound Of Digital Arteries For Distinguishing Primary From Secondary Raynaud’s Phenomenon
Abstract Number: 1829

Carboxypeptidase B2 Down-Regulates Osteoclast Activation In Inflammation
Abstract Number: 739

Cardiac Involvement In Granulomatosis With Polyangiitis
Abstract Number: 406

Cardiovascular Case Fatality In Rheumatoid Arthritis Is Decreasing; Results From a Current Low Disease Activity Rheumatoid Arthritis Cohort and Review Of The Literature
Abstract Number: 266

Cardiovascular Disease In Osteoarthritis: Hip Versus Knee and The Influence Of Multiple Symptomatic Joint Involvement
Abstract Number: 2448

Cardiovascular Disease Is Associated With Worse Functional Outcomes In Ankylosing Spondylitis
Abstract Number: 833

Cardiovascular Diseases In Rheumatoid Arthritis: Can Early Treatment With Disease-Modifying Antirheumatic Drugs Alter The Risk?
Abstract Number: 225

Cardiovascular Involvement In Erdheim-Chester Disease: A Magnetic Resonance Imaging Study On Seven Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].